Skip to main content

Table 4 The association between clinicopathological characteristics and CR status in ESCC patients received CCRT

From: A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer

Variables

Training set (n = 160)

P

Validation set (n = 66)

P

CR

Non-CR

CR

Non-CR

Age (years), mean ± SD

66.18 ± 9.55

64.55 ± 10.56

0.337

65.64 ± 10.09

66.48 ± 8.88

0.730

Gender

  

0.064

  

0.258

 Male

36 (30.8)

81 (69.2)

 

15 (31.2)

33 (68.8)

 

 Female

20 (46.5)

23 (53.5)

 

7 (38.9)

11 (61.1)

 

Tumor location

  

0.221

  

0.216

 Cervical

4 (40.0)

6 (60.0)

 

2 (50)

2 (50)

 

 Upper thoracic

16 (41.0)

23 (59.0)

 

6 (50)

6 (50)

 

 Middle thoracic

32 (36.8)

55 (63.2)

 

13 (32.5)

27 (67.5)

 

 Lower thoracic

4 (16.7)

20 (83.3)

 

1 (50%)

1 (50%)

 

Clinical stage

  

< 0.001

  

0.016

 I

1 (100.0)

0 (0)

 

1 (100.0)

0 (0)

 

 II

12 (70.6)

5 (29.4)

 

5 (50.0)

5 (50.0)

 

 III

40 (43.5)

52 (56.5)

 

14 (42.4)

19 (57.6)

 

 Iva

3 (6.0)

47 (94.0)

 

2 (9.1)

44 (90.9)

 

Radiation dose, median (range)

64 (61.25–66)

64 (62–66)

0.221

63 (60–65.75)

63 (60–65.75)

0.737

Chemotherapy regimen

  

0.209

  

0.831

 PF

43 (38.1)

70 (61.9)

 

17 (32.7)

35 (67.3)

 

 TP

13 (27.7)

34 (72.3)

 

5 (35.7)

9 (65.3)

 

LDH

  

0.226

  

0.587

 High

24 (30.4)

55 (69.6)

 

7 (29.2)

17 (70.8)

 

 Normal

32 (39.5)

49 (60.5)

 

15 (35.7)

27 (65.3)

 

NLR, median (range)

2.59 (1.72–3.14)

2.87 (2.01–3.99)

0.033

2.80 (1.88–3.58)

2.9 (1.56-.3.90)

0.935

PLR, median (range)

128 (100.20–160.47)

139.74 (103.63–181.40)

0.158

127.37 (95.64–192.44)

148.26 (94.90–197.13)

0.924

Rad-score, mean ± SD

− 13.39 ± 3.39

− 17.58 ± 3.58

< 0.001

− 13.87 ± 3.30

− 16.81 ± 3.51

< 0.001